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AbstrACt
Introduction There are more people living with dementia 
in low- and middle-income countries (LMICs) than in 
high-income countries. Evidence-based interventions 
to improve the lives of people living with dementia and 
their carers are needed, but a systematic mapping of 
methodologically robust studies in LMICs and synthesis 
of the effectiveness of dementia interventions in these 
settings is missing.
Methods and analysis A systematic review and meta-
analysis will be conducted to answer the question: Which 
dementia interventions were shown to be effective in 
LMICs and how do they compare to each other? Electronic 
database searches (MEDLINE, EMBASE, PsycINFO, CINAHL 
Plus, Global Health, WHO Global Index Medicus, Virtual 
Health Library, Cochrane CENTRAL, Social Care Online, 
BASE, MODEM Toolkit, Cochrane Database of Systematic 
Reviews) will be complemented by hand searching of 
reference lists and local knowledge of existing studies 
from an international network of researchers in dementia 
from LMICs. Studies will be eligible for inclusion if they 
were published between 2008 and 2018, conducted in 
LMICs and evaluated the effectiveness of a dementia 
intervention using a study design that supports causal 
inference of the treatment effect. We will include both 
randomised and non-randomised studies due to an 
anticipated low number of well-conducted randomised 
trials in LMICs and potentially greater external validity 
of non-randomised studies conducted in routine 
care settings. In addition to narrative synthesis of the 
interventions, feasibility of pairwise and network meta-
analyses will be explored to obtain pooled effects of 
relative treatment effects.
Ethics and dissemination Secondary analysis of 
published studies, therefore no ethics approval required. 
Planned dissemination channels include a peer-reviewed 
publication as well as a website, DVD and evidence 
summaries.
Prospero registration number CRD42018106206.
IntroduCtIon
More people with dementia are now living 
in low- and middle-income countries 
(LMICs) compared with high-income coun-
tries.1 Dementia is described by the Alzhei-
mer’s Association as ‘an overall term that 
describes a group of symptoms associated 
with a decline in memory or other thinking 
skills severe enough to reduce a person's 
ability to perform everyday activities’.2 Like 
other mental disorders, it places a signifi-
cant burden on societies in LMICs, where 
care is often provided by family members 
and/or financed out-of-pocket, magnifying 
its impact beyond the individual living with 
strengths and limitations of this study
 ► This protocol defines the scope, inclusion/exclu-
sion criteria and analytical approach for the first 
comprehensive assessment of methodologically 
robust dementia intervention studies in low- and 
middle-income countries (LMICs), the setting where 
most people with dementia currently live.
 ► Eligible study designs include both randomised trials 
and non-randomised studies supporting causal in-
ference of treatment effects, with stringent eligibility 
criteria applied for the latter.
 ► Planned analyses include a narrative synthesis map-
ping out the interventions studied in LMICs as well 
as traditional pairwise and network meta-analysis, 
capable of yielding relative treatment effect esti-
mates for interventions that have been compared 
either directly or indirectly (through a common com-
parator) to each other.
 ► A low number of studies may be eligible for inclu-
sion, potentially limiting the scope for quantitative 
meta-analysis.
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the condition.3 While no curative treatment for dementia 
exists, a range of interventions aimed at improving the 
lives of people living with dementia and their carers 
have been developed and progress made in evaluating 
and understanding which of these are effective.4 Despite 
the large and increasing burden of dementia in LMICs, 
these interventions have been primarily evaluated in 
high-income settings. Better understanding of the impact 
of dementia in LMICs and how people living with the 
disease can be better supported are therefore consid-
ered to be a priority.5 Building capacity for research and 
policy-making is at the heart of the recently launched 
strengthening responses to dementia in developing 
countries (STRiDE) project ( www. stride- dementia. org), 
as part of which a systematic review of the effectiveness of 
dementia interventions in LMICs will be conducted.
Research on dementia and dementia-related interven-
tions, many aiming to improve the quality of life of those 
who are affected by the condition and their carers, has 
increased considerably since it was recognised as a key 
challenge for care systems: in mid-2018, the Cochrane 
Database of Systematic Review ( www. cochranelibrary. 
com) listed over 120 systematic reviews of dementia-re-
lated interventions carried out since 2000 by their 
Dementia and Cognitive Improvement Group. Evidence 
on effectiveness and cost-effectiveness of a variety of 
dementia interventions has been recently summarised by 
other groups, prime among them the MODEM (model-
ling outcome and cost impacts of interventions for 
dementia) project.6 A comprehensive database of over 
1400 dementia intervention studies, along with a toolkit 
containing evidence summaries for decision-makers, 
people living with dementia and their carers was created 
(http:// toolkit. modem- dementia. org. uk/).
The increase in knowledge about disease aetiology, 
prevention and management is expected to contribute to 
better quality of life for people living with dementia and 
their carers through the implementation of evidence-
based approaches to diagnosing, managing and enhancing 
quality of life while living with the disease. The WHO,5 
organisations representing people living with dementia 
and their families,7 and researchers4 are all calling for 
decision-makers to focus on such approaches when devel-
oping policies and programmes. Evidence-based prac-
tices are informed by studies with strong research designs 
supporting a causal link between an intervention (be it 
a drug, non-pharmacological therapy, organisational 
change or another form of intervention) and improved 
outcomes in people living with dementia and their carers. 
While randomised controlled trials (RCTs) are consid-
ered the ‘gold standard’ of intervention studies, other 
study designs exist that allow researchers to draw causal 
conclusions about the effect of an intervention in the 
absence of RCTs and can provide essential evidence on 
‘what works’.8 9
Interventions with proven positive impacts in high-in-
come countries have previously been summarised in 
the MODEM Dementia Evidence Toolkit. However, it 
is unclear whether interventions that showed benefi-
cial effects in high-income settings, such as cognitive 
stimulation therapy for cognition and quality of life,10 11 
advance care planning,12 training for formal carers (such 
as Staff Training in Assisted Living Residences (STAR))13 
and support for family carers (STrAtegies for RelaTives 
(START)),14 are also effective in less-resourced settings, 
where awareness about dementia is lacking and dementia 
care may not be a policy priority. In this context, dementia 
is reported to be under-diagnosed and specialised care 
is often not available,7 raising the question of which 
dementia interventions are effective in LMICs. Indeed, 
previously developed recommendations for packages of 
dementia care in LMICs were largely based on evidence 
from high-income countries,7 15 indicating a need to 
better understand what works in LMICs. The aim of this 
systematic review is to help fill this research gap by iden-
tifying dementia interventions for which robust evidence 
on effectiveness in LMICs exists and to synthesise avail-
able evidence to determine which interventions have the 
most potential of achieving desired outcomes in these 
settings.
MEthods And AnAlysIs
This systematic review and meta-analysis protocol adheres 
to the Preferred Reporting Items for Systematic Review 
and Meta-Analysis Protocols checklist16 and was regis-
tered on the PROSPERO platform ( www. crd. york. ac. uk/ 
prospero): CRD42018106206.
review question
Which dementia interventions have been shown to be 
effective in low- and middle-income countries and how 
do they compare to each other?
Inclusion criteria
Population
We will include studies that have evaluated the effective-
ness of an intervention in adults (18 years and over) living 
with dementia or their carers.
We will include studies in all stages (including early- 
to late-stage dementia) and different forms of dementia 
(eg, Alzheimer’s disease, vascular dementia, Lewy bodies 
dementia and mixed dementias, as well as less common 
forms such as fronto-temporal dementia). We will also 
take into consideration risks of dementia associated with 
conditions such as HIV/AIDS that may be more preva-
lent in LMICs to ensure these are captured in our search 
strategy. Due to the particularly high risk of people with 
mild cognitive impairment (MCI) developing dementia 
(approximately one-third will develop dementia over 
a period of 3 to 10 years),17 we will also include studies 
focusing on this group.
Carers of people living with dementia include family 
members, other unpaid carers, as well as professional 
carers, irrespective of whether or not they are paid, and 
Protected by copyright.
 o
n
 O
ctober 3, 2019 at London School of Econom
ics & Politcal.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027851 on 19 June 2019. Downloaded from 
3Salcher-Konrad M, et al. BMJ Open 2019;9:e027851. doi:10.1136/bmjopen-2018-027851
Open access
whether or not they are living with the person they care 
for.
Studies will be included if they were conducted in a 
country considered a LMIC according to the Organi-
sation for Economic Co-operation and Development 
(OECD) categorisation at any time during the study 
period. The lists of aid recipient countries for the years 
2008 to 2018 were used to identify LMICs (http://www. 
oecd. org/ development/ financing- sustainable- develop-
ment/ development- finance- standards/ hist oryo fdac list 
sofa idre cipi entc ountries. htm).
We will include studies that were conducted entirely in 
LMICs, or (in the case of multi-country studies) where 
50% or more of study participants received the interven-
tion of interest in LMICs or where results were presented 
separately for participants in LMICs.
Intervention
One of the aims of this systematic review is to identify 
which interventions have been rigorously evaluated in 
LMICs. The eligibility criteria for types of interventions 
are therefore deliberately kept open: we will include all 
interventions that aim to improve the lives of people 
living with dementia and their carers contingent on the 
intervention having been subjected to a rigorous evalua-
tion (see eligible study designs below). We will apply an 
‘effectiveness’ perspective with respect to interventions, 
that is, interventions are eligible when defined as such 
in a study and improved outcomes are expected through 
the intervention.18 We will focus on people already living 
with dementia or MCI and their carers and will therefore 
exclude primary prevention studies (ie, prevention of 
dementia in people without cognitive impairment).
Dementia interventions can vary in terms of who they 
are targeting (person living with dementia, unpaid carers, 
care professionals and care systems), what the aim of the 
intervention is (secondary prevention, treatment, disease 
management, coping with caring for people living with 
dementia, managing the impact of dementia on the 
care system) and their mechanism (including diagnosis; 
pharmacological treatment; cognitive therapy; techno-
logical interventions; training; exercise; sleep therapy; 
music therapy; organisation of care, including advance 
care directives and case management; support for carers; 
financing of care; policy interventions and others).4
Comparison
All comparisons will be eligible, including active compar-
ators, usual practice/standard care/placebo and no 
action.
Outcomes
Outcomes of dementia intervention studies are highly 
heterogeneous and may vary by who is affected (person 
living with dementia, their carer(s), wider society and 
care system) and type of outcome (clinical outcomes, 
such as cognitive, neurological, psychological, psychoso-
cial; quality of life and functioning outcomes; care and 
delivery of care, such as the use of feeding tubes, hospi-
talisations, institutionalisations; economic outcomes; 
diagnosis rates; knowledge of the disease and ability 
to cope with caring for people with dementia). For 
example, recommendations on dementia interventions 
were recently made based on a review of the evidence on 
outcomes in domains ranging from, among others, cogni-
tion and neuropsychiatric outcomes to end-of-life care 
and care delivery.4
Given the broad range of potentially relevant outcomes, 
a search strategy that captures all of these is not feasible. 
Restricting inclusion criteria to certain types of outcomes 
would risk excluding potentially important parts of the 
evidence base for dementia interventions in LMICs. The 
impact of dementia is recognised to be experienced by 
different people and at different levels, including by 
people living with dementia, their carers, communities 
and the care system and wider society,19 and interven-
tions therefore need to take all of these perspectives into 
account.5
Study design
The research question we aim to answer is what works in 
dementia in LMICs. We are therefore interested in the 
effect that an intervention had on outcomes in people 
receiving the intervention, their carers and the wider 
care system.20 Accordingly, we will apply a causal infer-
ence framework in this review: study designs eligible for 
inclusion are those that support a causal link between 
the intervention and observed outcomes. This includes 
experimental designs (RCTs and cluster-RCTs) as well as 
non-randomised designs suitable for causal inference, 
defined as ‘comparisons of ‘potential outcomes’ (…) 
under different treatment conditions on a common set 
of units’.8 We will include both randomised and non-ran-
domised studies due to an anticipated low number of 
well-conducted randomised trials in LMICs, based on 
previous work (searches conducted for the MODEM 
Evidence Toolkit, and a previous review on packages of 
care for people living with dementia in LMICs15). Also, 
non-randomised studies may have greater generalis-
ability beyond the studied environment when conducted 
in settings and populations closer resembling routine 
practice.
In order to maximise the number of eligible studies and 
synthesise as much robust evidence about dementia inter-
ventions in LMICs as possible, we will extend the eligi-
bility criteria used by the Cochrane Effective Practice and 
Organisation of Care (EPOC) Group21 to also include 
other quasi-experimental study designs in addition to 
those typically seen in methodologically robust evaluation 
studies (non-randomised controlled trials, controlled 
before-after studies and interrupted time series studies). 
The label ‘quasi-experimental’ is discipline-specific and 
members of the Cochrane Non-Randomised Studies for 
Interventions Methods Group therefore developed a 
‘label-free’ taxonomy of quasi-experimental studies that 
aims to define such studies through a series of questions 
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in six domains.22 We will use their checklist to guide the 
selection of studies by study design (see table 1). Since we 
anticipate a shortage of methodologically robust studies 
of dementia interventions in LMICs, but still aim to 
synthesise the best available evidence that supports causal 
inference of treatment effects, we adapted the original 
checklist by removing restrictions to answer ‘yes’ to only 
one question in domains 2, 3 and 4. This will enable us 
to include several strong experimental and quasi-exper-
imental study designs, including RCTs (including clus-
ter-RCTs), non-randomised controlled trials, controlled 
before-after studies, interrupted time series studies, 
Table 1 Checklist for eligible study designs (based on Reeves et al22)
Feature
Eligible for inclusion 
if…
1. Was the intervention/comparator:
  Allocated to (provided for/administered to/chosen by) individuals? Yes
  Allocated to (provided for/administered to/chosen by) clusters of individuals? Yes
  Clustered in the way it was provided (by practitioner or organisational unit)? Yes
2. Were outcome data available:
  After intervention/comparator only (same individuals)? No
  After intervention/comparator only (not all same individuals)? No
  Before (once) AND after intervention/comparator (same individuals)? Yes
  Before (once) AND after intervention/comparator (not all same individuals)? Yes
  Multiple times before AND multiple times after intervention/comparator (same individuals)? Yes
  Multiple times before AND multiple times after intervention/comparator (not all same individuals)? Yes
3. Was the intervention effect estimated by:
  Change over time (same individuals at different time points)? Yes
  Change over time (not all same individuals at different time points)? Yes
  Difference between groups (of individuals or clusters receiving either intervention or comparator)? Yes
4. Did the researchers aim to control for confounding (design or analysis)
  Using methods that control in principle for any confounding? Yes
  Using methods that control in principle for time-invariant unobserved confounding? Yes
  Using methods that control only for confounding by observed covariates? No
5. Were groups of individuals or clusters formed by
  Randomisation? Yes
  Quasi-randomisation? Yes
  Explicit rule for allocation based on a threshold for a variable measured on a continuous or ordinal 
scale or boundary (in conjunction with identifying the variable dimension, below)?
Yes
  Some other action of researchers? Yes
  Time differences? Yes
  Location differences? Yes
  Healthcare decision makers/practitioners? Yes
  Participants' preferences? Yes
  Policymaker? Yes
  On the basis of outcome? No
  Some other process? (specify) -
6. Were the following features of the study carried out after the study was designed
  Characterisation of individuals/clusters before intervention? Yes
  Actions/choices leading to an individual/cluster becoming a member of a group? Yes
  Assessment of outcomes? Yes
7. Were the following variables measured before intervention:
  Potential confounders? Yes
  Outcome variable(s)? Yes
Protected by copyright.
 o
n
 O
ctober 3, 2019 at London School of Econom
ics & Politcal.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027851 on 19 June 2019. Downloaded from 
5Salcher-Konrad M, et al. BMJ Open 2019;9:e027851. doi:10.1136/bmjopen-2018-027851
Open access
difference-in-differences studies, instrumental variables 
studies, regression discontinuity design studies and other 
study designs that employ methods such as propensity 
score matching that attempt to control for observed and 
unobserved confounders.
As a contingency plan in case no such studies can be 
identified in LMICs, we define a secondary set of inclu-
sion criteria to still capture intervention studies in LMICs 
with less robust designs but that could still inform our 
understanding of what works in dementia in LMICs in 
the absence of better study designs. The secondary set of 
inclusion criteria will mirror the primary inclusion criteria, 
with the exception of study design. In the secondary set of 
inclusion criteria, studies will also be eligible for inclusion 
if they control only for observed confounders (criterion 
4 in table 1).
Publication type
We will include peer-reviewed journal articles, including 
primary publications of intervention studies and system-
atic reviews of these, and grey literature describing eval-
uations of dementia interventions in LMICs (eg, PhD 
theses and reports published by care system administra-
tive bodies and non-governmental organisations). System-
atic reviews are only eligible for inclusion if their focus 
is on LMICs (ie, if LMICs were specified as geographical 
setting in their inclusion criteria) and we will use these 
to identify primary studies eligible for inclusion (eligible 
if 50% or more participants were in LMICs or results 
were reported separately for LMIC settings). We will 
also include conference abstracts, provided they contain 
information to assess eligibility for inclusion.
Exclusion criteria
Exclusion criteria are listed in box 1.
search strategy
We will conduct searches in bibliographic databases 
(box 2), using text words, subject headings and other 
search functions that each database offers. We will limit 
the searches to studies published from 2008 to 2018 
and, where possible, will use filters to exclude editorials, 
commentaries and letters to the editor, as well as running 
a search filter for animal studies.
We will also make use of previous efforts to system-
atically capture studies evaluating the effectiveness of 
dementia interventions and will review studies identified 
by other authors for inclusion. First, we will review studies 
included in the MODEM Dementia Evidence Toolkit 
(http:// toolkit. modem- dementia. org. uk). The MODEM 
Toolkit contains over 1400 primary studies of dementia 
interventions. While the primary focus of the toolkit was 
on high-income settings, studies from LMICs may be 
included in the database. Second, we will screen existing 
Cochrane systematic reviews of dementia interventions 
for primary studies conducted in LMICs. We will review 
all Cochrane systematic reviews indexed in the Cochrane 
Library’s dementia and cognition topic.
In addition to database searches, we will scan the 
reference lists of included studies to capture potentially 
missed ones. We will use Google Scholar, Scopus and Web 
of Science to carry out citation searches for the included 
papers.
We will also capitalise on the expertise of STRiDE 
consortium partners (researchers and dementia advo-
cacy groups) in seven LMICs (Brazil, India, Indonesia, 
box 1 Exclusion criteria
We will exclude studies meeting any of the following conditions:
 ► Studies where less than 50% of participants received the inter-
vention of interest in low- and middle-income countries (LMICs) or 
where no results are available for a LMIC subgroup.
 ► Studies where no clear intervention was described.
 ► Studies of associations between exposure and outcome (as opposed 
to causal links between intervention and outcome).
 ► Studies of primary prevention of dementia.
 ► Studies where reports are not available in a language spoken by 
the international project team members (languages spoken in-
clude Arabic, Chinese, English, French, German, Bahasa Indonesia, 
Portuguese, Romanian, Spanish, Turkish and others).
 ► Studies that do not attempt to control for unobserved confounding, 
including cohort studies, case-control studies, cross-sectional stud-
ies and case series (unless these have applied methods to control 
for unobserved confounders).
 ► Narrative reviews, overview articles, editorials, commentaries, let-
ters to the editor.
 ► Studies where animals (as opposed to humans) received the 
intervention.
In case no studies meeting our primary inclusion criteria for study de-
sign can be identified, we will apply secondary inclusion criteria as 
specified under ‘Study design’ and will amend the exclusion criteria for 
study design accordingly.
box 2 online databases to be searched
 ► MEDLINE (via OVID).
 ► EMBASE (via OVID).
 ► PsycINFO (via OVID).
 ► CINAHL Plus (via EBSCO).
 ► Global Health (via CABI).
 ► WHO Global Index Medicus (GIM, includes databases from the six 
WHO regions: AIM (AFRO), LILACS (AMRO/PAHO), IMEMR (EMRO), 
IMSEAR (SEARO), WPRIM (WPRO)).
 ► Cochrane CENTRAL and Cochrane Database of Systematic Reviews.
 ► Social Care Online.
 ► BASE.
 ► Virtual Health Library.
In addition to the international databases listed above, we will consid-
er additional national or regional databases through consultation with 
strengthening responses to dementia in developing countries (STRiDE) 
partners in seven low- and middle-income countries (Brazil, India, 
Indonesia, Jamaica, Kenya, Mexico, South Africa). These databases 
might not be available in English and we will capitalise on the variety 
of languages spoken in the STRiDE consortium to include these in our 
search strategy, if deemed of sufficient added value for the identifica-
tion of studies meeting our inclusion criteria.
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Jamaica, Kenya, Mexico, South Africa), and an expanded 
network of STRiDE collaborators in other countries, to 
include published and unpublished studies from these 
and other countries meeting our eligibility criteria if they 
were not captured by database searches.
We will further search trials registers ( ClinicalTrials. gov 
and the International Clinical Trials Registry Platform) 
to identify ongoing or planned clinical trials of dementia 
interventions in LMICs.
We will capitalise on the expertise of information 
specialist support team of London School of Economics 
and Political Science (LSE) to finalise the search strategy.
Search terms
Search terms were selected to reflect the key concepts 
making up the review question: dementia interventions 
that have been studied using robust research designs in 
LMICs. Exemplary search terms for MEDLINE via OVID 
for the concepts of population and intervention, study 
design and LMICs are provided in table 2, including the 
number of hits for each search as per 10 October 2018. 
The search for MEDLINE will be translated for the other 
databases.
The ‘intervention’ concept provided in table 2 (lines 
22 to 98) includes both generic terms as well as a range 
of specific interventions that have been studied for 
dementia before, although usually in high-income coun-
tries. We based the list of specific interventions on a thor-
ough review of the evidence, conducted as part of the 
Lancet commission,4 and through revision by the inter-
national STRiDE consortium. While this might not be 
a comprehensive list of all interventions that have ever 
been studied for dementia, we aimed to increase the 
likelihood of identifying relevant studies by combining 
generic search terms pertaining to interventions, ther-
apies, etc with specific intervention types and names of 
interventions, such as drug names.
We will use established study design and geographical 
location search filters to narrow down the number of 
results and will make adaptations as necessary to reflect 
our inclusion criteria. If such filters are not available for 
some databases, we will consider adapting the search 
filters used for MEDLINE.
The search filters for eligible study designs are provided 
in table 2, rows 101 to 108 (for RCTs), 110 to 121 (for clus-
ter-RCTs) and 123 to 147 (for other quasi-experimental 
studies), respectively. In order to identify RCTs, we will 
use the sensitivity-maximising version of the highly sensi-
tive filter for RCTs recommended in the Cochrane Hand-
book.23 For identification of cluster-RCTs, we will use the 
sensitivity-maximising filter for cluster-RCTs developed by 
Taljaard et al.24 This filter was validated, among others, for 
a sample of cluster-RCTs in sub-Saharan Africa from before 
2001 and showed good sensitivity (94%), with overall 
higher sensitivity for more recent studies. For identifica-
tion of non-randomised studies that support causal infer-
ence of the relationship between exposure and outcome, 
we created an additional set of search terms pertaining 
to commonly used labels for quasi-experimental studies. 
We enhanced these search terms with the ‘aetiology’ filter 
developed by the Hedges Group.25 The methodological 
criteria used for developing the filter were found to be a 
good match for our inclusion criteria (including the use 
of a clearly identified comparison group, with examples 
given by the authors including ‘randomised controlled 
trials (RCT), quasi-randomised controlled trials, non-ran-
domised controlled trials, cohort studies with case-by-case 
matching or statistical adjustment to create comparable 
groups or nested case–control studies’25).
Finally, rows 149 to 157 of table 2 show the exemplary 
search terms for LMICs, based on a filter for LMICs that 
is available from the Cochrane EPOC website (http:// 
epoc. cochrane. org/ lmic- filters). The search terms were 
expanded and updated to reflect the list of LMICs from 
2008 to 2018.
Filters for LMICs and study designs were tested in 
MEDLINE for a sample of 10 studies (six selected for 
being conducted in LMICs,26–31 four selected for using 
quasi-experimental study designs32–35). The sensitivity 
of the search strategy for this sample was 100% (10/10 
studies) for searches with study design filters, and 100% 
(6/6 studies) when adding the LMIC filter.
study selection
Search results from the database searches will be exported 
to a bibliographic reference manager and deduplicated. 
Two researchers will independently screen articles at 
the title and abstract level for eligibility. Full text for 
articles deemed eligible at this stage will be retrieved, 
including articles where no abstract was available at the 
first screening. Articles describing the same study will be 
linked together. Full-text articles will be independently 
assessed for inclusion eligibility by two researchers. Devi-
ating decisions on inclusion will be resolved by discus-
sion and consensus between the two researchers. If no 
consensus is reached by the two researchers, we will 
consult with a third researcher for a final decision on 
inclusion. We will record rates of agreement between 
researchers independently screening abstracts and full 
texts to measure the extent of disagreement using the 
kappa statistic. We will take a kappa of >0.8 as indication 
of ‘very good’ agreement.36
Inclusion and exclusion of studies at each stage will be 
illustrated with a Preferred Reporting Items for System-
atic Reviews and Meta-Analyses flow chart.37 A list of 
included and excluded studies (with primary exclusion 
reason) will be made available.
data extraction
Two researchers will independently extract the informa-
tion listed in box 3 from included studies. Selection of 
data to be extracted was informed by the review ques-
tion and by practical insights regarding data extraction 
and synthesis from non-randomised studies.38 39 We will 
contact authors of included abstracts to obtain full details 
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Table 2 Exemplary search terms (MEDLINE via OVID)
Search # Terms used No. of hits
1 Exp Dementia/ 148 649
2 Dement*.mp 114 488
3 Amentia*.mp 102
4 (major adj3 cognit* adj3 disorder*).mp 159
5 (alzheimer* or alzeimer* or (cortical adj4 sclerosis)).mp 140 775
6 ((encephalopath* or cogniti* or neurocogniti*) adj4 (aids or acquired immun?deficiency syndrome or acquired immun? deficiency syndrome or hiv or human immun?deficiency virus 
or human immun? deficiency virus)).mp
3302
7 ‘Pick Disease of the Brain’/ 495
8 (Pick* disease).mp 3308
9 (lobar adj3 atroph* adj3 brain).mp 10
10 Huntington Disease/ 11 069
11 (Huntington* disease).mp 16 193
12 (Huntington* chorea).mp 1349
13 Lewy Body Disease/ 2761
14 (Lewy bod* adj3 disease).mp 4240
15 (cerebr* adj3 deteriorat*).mp 361
16 (cerebr* adj3 insufficien*).mp 2079
17 ((frontotemporal or fronto temporal or corticobasal or cortico basal or frontal lobe*) adj4 (degenerati* or dysfunction*)).mp 5217
18 ((cognit* or memory or cerebr*) adj3 (declin* or impair* or los* or deteriorat* or degenerat* or insufficen*)).mp 106 843
19 Cognitive Dysfunction/ 8749
20 (MCI or (mild adj2 cognit* impair*)).ti,ab. 20 332
21 Or/1–20 314 147
22 (Intervention* or therap* or treatment* or program* or manage* or prevent* or diagnos* or polic*).mp 12 485 776
23 exp Cognitive Therapy/ 23 692
24 (cognit* adj3 therap*).mp 30 470
25 (cognit* psycho therap* or cognit* psychotherap*).mp. 119
26 (cognit* adj3 training).mp 3571
27 (cognit* adj3 rehab*).mp 1911
28 Or/23–27 36 923
29 exp Drug Therapy/ 1 246 404
30 (Drug* or medicine* or pharmacotherap* or pharmaco* therap*).ti,ab. 1 838 638
31 exp Cholinesterase Inhibitors/ 47 229
32 cholinesterase agent*.mp 30
33 cholinesterase inhibitor*.mp 21 340
34 exp Antipsychotic Agents/ 115 322
35 (Tranquili* adj3 (agent* or drug*)).mp 12 096
Continued
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Search # Terms used No. of hits
36 Antipsychotic*.mp 63 916
37 (neuroleptic adj3 (agent* or drug*)).mp 3296
38 exp Serotonin Uptake Inhibitors/ 34 982
39 (serotonin uptake inhibitor* or serotonin reuptake inhibitor*).mp or ssri*.ti,ab 25 984
40 exp Benzodiazepines/ 62 786
41 Benzodiazepine*.mp 42 836
42 exp ‘Hypnotics and Sedatives’/ 115 358
43 (Sedative adj3 (effect* or agent*)).mp 5467
44 (memantine or donepezil or rivastigmine or galantamine or souvenaid or risperidone or haloperidol or olanzapine or quetiapine or citalopram or dextromethorphan or carbamazepine 
or mirtazapine or sertraline or moclobemide or trazodone or melatonin or ramelteon or methylphenidate).mp
105 057
45 Or/29–44 3 080 487
46 exp Exercise Therapy/ 42 856
47 Exercis*.mp 335 419
48 (Physical activit* or physical training).mp. 99 409
49 (Aerobic* or arobic*).mp 81 338
50 exp Exercise/ 166 405
51 Or/46–50 497 630
52 (social adj3 activit*).mp 9247
53 (social adj3 engag*).mp 2774
54 (social adj3 stimul*).mp 2178
55 Or/52–54 14 003
56 exp Psychotherapy/ 180 508
57 (psycholog* therap* or psychotherap*).mp 85 389
58 ((behavio?r* adj3 therap*) or (conditioning adj3 therap*)).mp 47 185
59 exp Counseling/ 40 343
60 Counsel?ing.mp 89 908
61 psychosocial support systems/ 145
62 ((Psychosocial or psycho social) adj3 (support or interven* or care)).ti,ab 11 193
63 Or/56–62 315 606
64 exp Complementary Therapies/ 208 840
65 ((Alternative or compl?ment* or traditional) adj3 (medicine* or therap*)).mp 101 303
66 Acupunct*.mp 25 265
67 (herb* adj3 (tea or remedy or remedies or medicine*)).ti,ab. 16 075
68 Gingko.ti,ab 346
69 homeopath*.mp 6178
70 ((music or art or aroma or light or photo or pet or pets) adj3 therap*).ti,ab 16 656
Table 2 Continued 
Continued
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Search # Terms used No. of hits
71 Massage.ti,ab 9025
72 (mind adj3 body).ti,ab 4035
73 Phototherapy/ 7273
74 Or/64–73 302 897
75 exp Advance care planning/ 8277
76 (Advance? adj3 (care or medical or healthcare) adj3 plan*).mp 3552
77 (decision* adj3 (aid* or support)).mp 41 646
78 Or/75–77 46 897
79 Case Management/ 9516
80 (communicati* adj3 skill* adj3 training).mp 1283
81 (dementia care adj3 map*).mp 92
82 ((person* or patient*) adj3 cent* adj3 care).mp 23 552
83 Or/79–82 34 244
84 (‘Resources for Enhancing Alzheimer’s Caregiver Health’ or ‘Strategies for Relatives’).ti,ab. 88
85 Caregivers/ed (Education) 2484
86 CAREGIVERS/px (Psychology) 18 509
87 Self-Help Groups/ 8626
88 exp Social support/ 63 885
89 Or/84–88 87 559
90 Diagnosis, Computer-Assisted/ 21 241
91 Telemedicine/ 17 577
92 (Telemedicine or tele medicine).mp 21 573
93 exp Computers, Handheld/ 5107
94 ((smart adj2 (phone* or device* or tablet*)) or smartphone*).mp 8280
95 cognitive aid*.mp. 138
96 Reminder*.ti,ab 10 667
97 Robot*.mp 38 250
98 Or/90–97 102 392
99 22 or 28 or 45 or 51 or 55 or 63 or 74 or 78 or 83 or 89 or 98 13 800 589
100 21 and 99 208 431
101 randomized controlled trial.pt 462 693
102 controlled clinical trial.pt 92 457
103 (randomized or randomised).ab 495 756
104 Placebo.ab 189 758
105 drug therapy.fs 2 024 910
106 Randomly.ab 292 598
Table 2 Continued 
Continued
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Search # Terms used No. of hits
107 Trial.ab 431 012
108 Groups.ab 1 806 682
109 Or/101–108 4 294 404
110 randomized controlled trial.pt 462 693
111 (Cluster* adj2 randomi*).tw 9224
112 ((communit* adj2 intervention*) OR (communit* adj2 randomi*)).tw 6858
113 Group* randomi*.tw 2846
114 Or/111–113 18 443
115 intervention?.tw 782 326
116 cluster analysis/ 56 328
117 health promotion/ 66 499
118 program evaluation/ 56 711
119 health education/ 57 721
120 Or/115–119 965 052
121 114 or 120 968 364
122 110 or 121 1 366 397
123 risk.mp. 2 178 921
124 exp cohort studies/ 1 751 258
125 between group.tw 21 162
126 Or/123–125 3 451 482
127 (non random* or nonrandom*).mp 33 945
128 Non-Randomized Controlled Trials as Topic/ 359
129 quasi.mp 41 169
130 (natural adj3 experiment).mp 1724
131 instrumental variable*.mp 1969
132 Cohort.mp 516 750
133 before-after.mp 4519
134 (before adj2 after adj study).mp. 1810
135 Controlled Before-After Studies/ 329
136 (difference-in-difference* or diff-in-diff).mp 1782
137 regression discontinuity.mp 223
138 Historically Controlled Study/ 139
139 historical* control.mp 3400
140 Interrupted Time Series Analysis/ 435
141 Interrupted Time Series.mp 2280
142 Case-control.mp 287 943
Table 2 Continued 
Continued
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Search # Terms used No. of hits
143 Case-Control Studies/ 249 334
144 Match*.mp 419 961
145 Propensity.mp 47 848
146 Propensity Score/ 5596
147 Or/127–146 1 205 777
148 126 or 147 4 094 244
149 Developing Countries.sh,kf. 81 106
150 (Africa or Asia or Caribbean or West Indies or South America or Latin America or Central America).hw,kf,ti,ab,cp. 242 209
151 (Afghan* or Albania* or Algeria* or Angola* or Anguilla* or Antigua* or Barbuda* or Argentin* or Armenia* or Azerbaijan* or Azeri or Bangladesh* or Barbad* or Benin* or Byelarus or 
Byelorussian or Belarus* or Belorussia* or Belize* or Bhutan* or Bolivia* or Bosnia* or Herzegovin* or Hercegovin* or Botswana or Botsuana or Motswana or Batswana or Brasil* 
or Brazil* or Burkina Faso or Burkina Fasso or Burkina* or Burundi* or Urundi* or Cambodia* or Cameroon* or Cameron* or Cape Verd* or Cabo Verde or Central African Republic 
or Chad* or Tchad* or Chile* or China or Chinese or Colombia* or Columbia* or Comoros or Comoro Islands or Comores or Comoran or Mayotte or Congo* or Costa Rica* or Cote 
d'Ivoire or Ivory Coast or Ivorian* or Cook Islands or Cuba* or Croat* or Djibouti* or Dominica* or East Timor or East Timur or Timor Leste or Timorese or Ecuador* or Equador* or 
Egypt* or El Salvador or Salvadoran or Eritrea* or Ethiopia* or Fiji* or Gabon* or Gambia* or Gaza or Georgia Republic or Georgian or Abkhazia* or Abchasia* or South Ossetia* or 
Ghana* or Grenada or Grenadian or Guatemala* or Guinea* or Guinea Bissau or Guian* or Guyana or Haiti* or Hondura* or India or Indian or Indonesia* or Iran* or Iraq* or Jamaica* 
or Jordan* or Kazakhstan* or Kazakh or Kenya* or Kiribati or Korea* or Kosovo or Kosova* or Kyrgyzstan or Kirghizia or Kyrgyz or Kirghiz or Kirgizstan or Lao PDR or Laos or Laotian 
or Lebanon or Lebanese or Lesotho or Mosotho or Basotho or Liberia* or Libya* or Macedonia* or FYROM or Madagasca* or Malagasy or Malaysia* or Malaya* or Malay or Sabah or 
Sarawak or Malawi* or Maldives or Maldivan or Mali or Malian or Marshall Islands or Marshallese or Mauritania* or Mauriti* or Agalega Islands or Mexico or Mexican or Micronesia* or 
Middle East* or Moldova* or Moldovia* or Transnistria* or Mongolia* or Montenegr* or Montserrat* or Morocc* or Mozambique or Mozambican or Myanmar* or Myanma or Burma or 
Burmese or Namibia* or Nauru* or Niue or Nepal* or Nicaragua* or Niger or Nigerien or Nigeria* or Oman* or Pakistan* or Palau* or Palestine or Palestinian or Panama or Panamanian 
or Paraguay* or Papua New Guinea* or Peru or Peruvian or Philippines or Philipines or Phillipines or Phillippines or Filipino or Philipino or Philippino or Phillipino or Phillippino or 
Rwanda* or Ruanda* or Saint Helen* or St Helen* or Saint Kitts or St Kitts or Kittian or Nevis* or Saint Lucia* or St Lucia* or Saint Vincent or St Vincent or Vicentian or Grenadines or 
Samoa* or Sao Tome* or Senegal* or Serbia* or Seychell* or Sierra Leone* or Sri Lanka* or Ceylon or Solomon Island* or Somali* or South Africa* or Sudan or Sudanese or Surinam* 
or Swaziland or Swazi or Eswatini or Syria or Syrian or Tajikistan or Tadzhikistan or Tadjikistan or Tajik or Tadzhik or Tanzania* or Thailand or Thai or Togo or Togolese or Tonga* or 
Tunisia* or Tokelau or Trinidad* or Tobago* or Turkey or Turkish or Turks or Turkmenistan or Turkmen or Tuvalu* or Uganda* or Ukraine or Ukrainian or Uruguay* or Uzbekistan* or 
Uzbek or Vanuatu or Venezuela* or Vietnam* or Viet Nam or Wallis Futuna or West Bank or Yemen* or Zambia* or Zimbabwe*).hw,kf,ti,ab,cp.
2 805 600
152 ((developing or less* developed or under developed or underdeveloped or middle income or low* income or underserved or under served or deprived or poor*) adj (countr* or nation? 
or population? or world)).ti,ab.
85 468
153 ((developing or less* developed or under developed or underdeveloped or middle income or low* income) adj (economy or economies)).ti,ab. 440
154 (low* adj (gdp or gnp or gross domestic or gross national)).ti,ab. 217
155 (low adj3 middle adj3 countr*).ti,ab. 11 181
156 (lmic or lmics or third world or lami countr*).ti,ab. 5792
157 transitional countr*.ti,ab. 146
158 Or/149–157 2 945 907
159 100 and (109 or 122 or 148) and 158 8278
160 limit 159 to (comment or editorial or letter) 74
161 159 not 160 8204
162 limit 161 to yr=‘2008 -Current’ 6322
163 exp animals/not humans.sh. 4 496 553
164 162 not 163 5786
Table 2 Continued 
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of their studies if the information is not available from 
abstracts.
risk of bias
We will assess the internal validity of included studies using 
appropriate tools. For RCTs, we will use the Cochrane 
Collaboration’s recently updated risk of bias tool (RoB 
2.0).40
We will use the Cochrane Collaboration’s ROBINS-I 
tool to assess risk of bias in non-randomised studies.41
data synthesis
We will first describe the interventions that have been 
evaluated in rigorous study designs in LMICs and 
summarise the features of the intervention, where they 
were studied, characteristics of the studies and their find-
ings. We are planning to tabulate interventions according 
to who they are targeted at (person living with dementia, 
their carers, care professionals and care systems), aim 
of the intervention (secondary prevention, treatment, 
disease management, coping with the disease and caring 
for people living with dementia, managing the impact 
of dementia on the care system), intervention type 
(including, but not limited to, pharmaceuticals, cognitive 
therapy, technological interventions, exercise, training, 
diagnosis, organisation of care, financing of care, policy 
interventions) and outcomes studied. We plan to review 
details extracted from included studies on the popula-
tion, intervention and outcomes (see box 3) to group 
studies accordingly. For example, in terms of population, 
included studies may be grouped according to severity of 
impairment (for people living with dementia) and type of 
carer (unpaid, paid, professional, family caregiver). Tabu-
lation along this dimension will allow us to explore which 
types of interventions were shown to be effective for each 
of the groups in order to provide sufficiently granular 
findings to inform decision-making in specific contexts. 
Similarly, we plan to tabulate studies according to the 
aim of the intervention, intervention type and outcome 
studied, thereby providing a summary of the evidence for 
different aspects of dementia interventions.
Potentially relevant outcomes for this systematic review 
can be characterised by their type and the stakeholder 
group they refer to. A draft list of potentially relevant 
outcomes and their stakeholder groups according to 
which our analysis can be structured is provided in the 
online supplementary table. The list is subject to change 
after reviewing the outcomes used in included studies, 
which might use other outcomes that could necessitate a 
different categorisation.
We will use the GRADE approach to rate the quality of 
evidence for each intervention.42
Quantitative synthesis
We will explore the feasibility of conducting quantita-
tive synthesis of treatment effects through traditional 
pairwise and network meta-analysis. Feasibility of quan-
titative synthesis will be assessed for each intervention 
studied in our sample of included studies. We will assess 
the similarity of the specific intervention in each study 
with other candidate interventions for a meta-analysis, 
the participants in the studies where this intervention 
was evaluated and whether the same outcome was used. 
Quantitative synthesis can only be conducted for studies 
reporting the same outcome, although individual studies 
may use different instruments to measure this (eg, the 
Mini-Mental State Examination (MMSE) and Alzheimer's 
Disease Assessment Scale–cognitive subscale (ADAS-cog) 
for cognition, and the Texas Functional Living Scale and 
Barthel scale for activities of daily living).
We will assess the feasibility to conduct both traditional 
pairwise and network meta-analysis. Pooled estimates are 
calculated as weighted averages of the treatment effects 
in included studies, where weights are assigned to each 
study based on its precision.43 Network meta-analysis 
extends pairwise meta-analysis by incorporating both 
direct evidence about the relative effectiveness of inter-
ventions that have been compared with each other in a 
primary study and indirect evidence about the relative 
effectiveness of interventions that were never directly 
compared with each other, but are connected through a 
network of other interventions for which direct compar-
isons exist. In addition, network meta-analysis can be a 
box 3 data to be extracted from included studies
 ► Publication details.
 ► Source of funding for the study.
 ► Geographical location.
 ► Care setting.
 ► Study design: description and coding of the study design and how 
causality of a treatment effect was supported, including which co-
variates were used in the analysis to control for confounding and 
judgement about whether criteria for causality for the specific study 
design were met (in the case of non-randomised studies).
 ► Participant details, including type of dementia and representative-
ness of local/regional/national population with dementia.
 ► Intervention: brief description of the intervention in terms of its aims, 
implementation and intervention details, including for example, du-
ration and intensity of the intervention, dosage of drugs, existence 
of a protocol or manual for psychosocial, training or education inter-
ventions and other details that allow an informed judgement about 
the comparability of interventions within the same type of treatment.
 ► Comparator: description of the comparison group and the interven-
tion received by them (if any), including a note on statistically signif-
icant differences in baseline characteristics between experimental 
and control groups.
 ► Outcomes: primary and secondary outcomes of the study, including 
information on how they were measured (instruments used).
 ► Results: effect size and measure of its variance for the primary out-
come and for any other outcomes mentioned in the abstract or ex-
ecutive summary of the study. Preference will be given to adjusted 
effect sizes (ie, taking into account covariates that might not be bal-
anced across experimental and control group), and in cases where 
several adjusted results are presented we will extract the one where 
selection bias is best controlled (either through design or analysis, 
eg, inclusion of most relevant confounding variables).
 ► Risk of bias information.
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valuable tool in delineating the effects of individual 
components of complex interventions, as recently shown 
in a network meta-analysis of multi-component interven-
tions for dementia caregiver depression.44 The validity 
of treatment effect estimates obtained through network 
meta-analysis depends on the similarity of the various 
direct comparisons in the network with respect to rele-
vant treatment effect modifiers (eg, severity of disease, 
age of participants, risk of bias due to study design and 
implementation) and consistency of treatment effects 
obtained from direct and indirect comparisons.45
It is anticipated that in our sample of included studies, 
there will be underlying differences between individual 
studies of the same intervention, in particular with 
respect to the details of the intervention and the setting. 
For example, a training intervention in one study is 
unlikely to be exactly the same intervention as in another 
study, even if a protocol is used to standardise the inter-
vention, because, for example, the individual delivering 
the training changes. Such differences do not preclude 
pooling study results, but the heterogeneity in treatment 
effects resulting from underlying differences needs to be 
taken into account when assigning weights to studies for 
a pooled estimate. Our default will therefore be to use a 
random-effects model, which takes into account between-
study variation and assumes that included studies come 
from different populations, with unique details of the 
intervention and conditions of the study. The true treat-
ment effect can therefore vary from study to study.46
Subgroup analysis
While a random-effects model takes into account between-
study variation, it does not explain heterogeneity. We will 
aim to use subgroup analysis and meta-regression to iden-
tify any study-level characteristics that might explain vari-
ation in treatment effects. Potential candidate covariates 
for subgroup analysis and meta-regression are study design 
and quality (within RCTs: risk of bias; within non-RCTs: 
analytical method employed, for example, instrumental 
variable, risk of bias), intervention details (eg, drug dose, 
intensity of training, intensity of stimulation therapy) and 
setting (by country, by bracket of gross national income, 
by rural vs urban setting). However, subgroup analysis will 
only produce meaningful insights when enough studies 
are included in each subgroup to detect any difference by 
the selected covariate (as opposed to a chance finding) 
and meta-regression should not be conducted for samples 
of less than 10 studies.47 Given that we do not expect to 
identify a large number of robust dementia intervention 
studies in LMICs, it is unlikely that there will be sufficient 
studies of a given intervention with a specific outcome to 
allow meaningful subgroup analysis and meta-regression.
In cases where interventions were evaluated both by 
RCTs and non-randomised studies, we will obtain sepa-
rate pooled effects for the two study types.18 We will 
extract information on study design characteristics that 
will allow us to examine these as potential sources of 
heterogeneity.38
Exploring meta-bias
For each intervention-outcome pair, we will first assess in 
a funnel plot whether asymmetry exists with respect to 
expected random variation of treatment effects around 
the pooled effect estimate with decreasing study preci-
sion. Funnel plots are used to detect possibly ‘missing’ 
smaller studies with larger or smaller treatment effects 
than what would be expected by chance alone, for which 
publication bias is one possible explanation.48 We will 
then use contour-enhanced funnel plots to assess whether 
any observed asymmetry is likely due to publication 
bias favouring the publication of statistically significant 
results.49
We anticipate identifying only a small number of studies 
eligible for inclusion in our quantitative review (meeting 
the criteria of being conducted in a LMIC and using a 
robust study design). In a scenario where not more than 
one LMIC study exists for any combination of interven-
tion and outcome, pairwise meta-analysis will become 
impossible. For network meta-analysis, the existence 
of only a handful of LMIC studies, even if a common 
comparator (eg, standard care) exists, makes it difficult 
to assess whether the assumptions of similarity (with 
respect to treatment effect modifiers) and consistency 
(agreement between direct and indirect estimates of 
treatment effect) hold. In case of a lack of eligible studies 
meeting our primary inclusion criteria, we will use our 
secondary set of inclusion criteria for studies using less 
robust research designs and will explore the feasibility of 
quantitative synthesis of these.
Given the reliance of past efforts to develop recommen-
dations for dementia interventions in LMICs on evidence 
from high-income countries,7 15 our primary aim is to 
advance our understanding of what works in LMICs and 
provide policymakers, people living with dementia and 
their carers, health and care professionals and others with 
evidence that is of immediate relevance to their setting. 
However, should quantitative synthesis of LMIC studies 
not be feasible due to a lack of studies reporting the same 
outcome, we will pursue an alternative way of obtaining 
pooled estimates of the comparative effectiveness of 
dementia interventions relevant for LMICs, as outlined 
below. In a scenario where we are unable to identify 
enough primary studies of dementia interventions in 
LMICs, we will quantitatively synthesise available evidence 
from methodologically robust studies from high-income 
countries, as identified in the MODEM Toolkit ( www. 
modem- dementia. org. uk). We will discuss existing inter-
ventions with dementia experts from the STRiDE partner 
countries to identify those that have the highest relevance 
for LMICs. We will then extract relevant information 
from studies meeting our study design inclusion criteria 
in the MODEM database and obtain pooled estimates for 
the effectiveness and comparative effectiveness of these 
interventions. We will develop a separate protocol for this 
approach should it become necessary (ie, in the case of 
not identifying eligible studies in LMICs).
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Patient and public involvement
While no people living with dementia or carers were 
involved in the development of this protocol, the 
research project under which this systematic review will 
be undertaken (STRiDE), was developed in close collab-
oration with dementia advocacy groups and experts by 
experience. People living with dementia and carers will 
be involved in later stages of the systematic review process 
(selection of relevant interventions for wider dissemina-
tion as described below).
EthICs And dIssEMInAtIon
No primary data collection will be conducted. We will 
include published reports of studies and will synthesise 
results of these at the aggregate level. We therefore did 
not seek ethics approval.
We plan to publish the findings of this systematic review 
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